Finance

Lists
4506:TYO
Sumitomo Pharma Co Ltd
1 622,00 JP¥
+1,92%
(+30,50) 1D
13 հոկ, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4506...
Open
1 632 JP¥
High
1 642 JP¥
Low
1 600 JP¥
Mkt. cap
728,61 մլրդ
Avg. vol.
3,50 մլն
Volume
3,45 մլն
P/E ratio
5,80
52-wk high
3 288 JP¥
52-wk low
1 188 JP¥
EPS
280 JP¥
Shares outstanding
397,30 մլն
No. of employees
3 հզր
Open
1 632 JP¥
High
1 642 JP¥
Low
1 600 JP¥
Mkt. cap
728,61 մլրդ
Avg. vol.
3,50 մլն
Volume
3,45 մլն
P/E ratio
5,80
52-wk high
3 288 JP¥
52-wk low
1 188 JP¥
EPS
280 JP¥
Shares outstanding
397,30 մլն
No. of employees
3 հզր
News stories
From web sources and news partners
Profile
Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka. Wikipedia
About Sumitomo Pharma Co Ltd
CEO-
Employees3,12 հզր
Founded14 մյս, 1897 թ.
HeadquartersՕսակա, Osaka, Ճապոնիա
Sector-
Last report
31 հլս, 2026 թ.
Fiscal period
Q1 2027
- / -
Revenue / Est. (JPY)
129,50 մլրդ / 114,10 մլրդ
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
119,12 մլրդ
120,62 մլրդ
105,55 մլրդ
129,50 մլրդ
Cost of goods sold
45,59 մլրդ
55,44 մլրդ
51,26 մլրդ
61,41 մլրդ
Cost of revenue
45,59 մլրդ
55,44 մլրդ
51,26 մլրդ
61,41 մլրդ
Research and development expenses
9,35 մլրդ
10,35 մլրդ
16,12 մլրդ
11,43 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
40,90 մլրդ
42,94 մլրդ
43,52 մլրդ
39,24 մլրդ
Operating expense
-1,04 մլրդ
52,19 մլրդ
110,09 մլրդ
50,33 մլրդ
Total operating expenses
44,55 մլրդ
107,63 մլրդ
161,36 մլրդ
111,74 մլրդ
Operating income
74,57 մլրդ
13,00 մլրդ
-55,81 մլրդ
17,75 մլրդ
Other non operating income
-
-
-1,64 մլրդ
-
EBT including unusual items
80,87 մլրդ
8,74 մլրդ
-1,20 մլրդ
18,30 մլրդ
EBT excluding unusual items
80,87 մլրդ
8,74 մլրդ
-51,00 մլրդ
18,30 մլրդ
Income tax expense
-6,78 մլրդ
-80,00 մլն
-383,00 մլն
1,30 մլրդ
Effective tax rate
-8,39%
-0,92%
32,05%
7,09%
Other operating expenses
-51,30 մլրդ
-1,10 մլրդ
50,45 մլրդ
-337,00 մլն
Net income
87,65 մլրդ
8,82 մլրդ
-812,00 մլն
17,00 մլրդ
Net profit margin
73,58%
7,31%
-0,77%
13,13%
Earnings per share
-
-
-
-
Interest and investment income
5,11 մլրդ
258,00 մլն
4,64 մլրդ
2,20 մլրդ
Interest expense
-
-5,14 մլրդ
-
-2,09 մլրդ
Net interest expenses
5,11 մլրդ
-4,88 մլրդ
4,64 մլրդ
107,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
79,85 մլրդ
18,32 մլրդ
-52,48 մլրդ
22,65 մլրդ
Gain or loss from assets sale
1,96 մլրդ
-
-
-
AI content may include mistakes. Learn more
Google Apps